AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18314118 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 150
Study 17239277 — intervention group
Group type: EXPERIMENTAL
Intervention: Microarray analysis for gene expression profiling
Number of subjects: 0
Study 17239277 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of differential expression, chromosomal alteration, and pathways signature analysis
Number of subjects: 0
Study 14725610 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-containing coffee
Number of subjects: 12
Study 14725610 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 12
Study 11774270 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer using serum prostate-specific antigen (PSA) and digital rectal examination (DRE) as an ancillary test.
Number of subjects: 102691
Study 11774270 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer in the ERSPC trial.
Number of subjects: 102691
Study 11774270 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening adherence in the intervention arm.
Number of subjects: 102691
Study 11774270 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-based centers with randomization prior to consent.
Number of subjects: 102691
Study 11774270 — intervention group
Group type: COMPARATOR
Intervention: Comparison of mean age-specific PSA levels between PLCO and ERSPC trials.
Number of subjects: 102691
Study 9419169 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir, 8 g/day
Number of subjects: 1227
Study 9419169 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir, 3.2 or 0.8 g/day
Number of subjects: 1227
Study 8575495 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 MU
Number of subjects: 127
Study 8575495 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 MU
Number of subjects: 127
Study 2539346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 03-8799 (0.75 g/m2) and SR 2508 (2 g/m2) administered three times per week for 15 doses
Number of subjects: 26
Study 2539346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 03-8799 (0.75 g/m2) and SR 2508 (2 g/m2) administered three times per week for 12 doses
Number of subjects: 26
Study 2539346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 03-8799 and SR 2508 combination
Number of subjects: 26
Study 311458 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 58
Study 311458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 58
Study 311458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 31385620 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue Line Ultra Suctionaid (BLUSA) talking tracheostomy tube (Smiths Medical)
Number of subjects: 22
Study 31223399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of ketoprofen 100mg
Number of subjects: 300
Study 31223399 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine and prilocaine topical cream
Number of subjects: 300
Study 31223399 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (placebo)
Number of subjects: 300
Study 27558280 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (AZL-M) 40 mg
Number of subjects: 449
Study 27558280 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (AZL-M) (all doses)
Number of subjects: 449
Study 27558280 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan medoxomil (OLM) 20 mg
Number of subjects: 449
Study 27558280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 26499123 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade-6 HIV-prevention intervention
Number of subjects: 3924
Study 26499123 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade-10 HIV-risk reduction intervention
Number of subjects: 3924
Study 26499123 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined child and parent-child HIV-risk reduction interventions
Number of subjects: 3924
Study 26499123 — intervention group
Group type: EXPERIMENTAL
Intervention: Both grade-6 and grade-10 interventions
Number of subjects: 3924
Study 23250194 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent physical activity (PA)
Number of subjects: 356
Study 23250194 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month physical activity (PA)
Number of subjects: 356
Study 23082419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring and identification of the external branch of the superior laryngeal nerve (EBSLN) during thyroid surgery.
Number of subjects: 42
Study 23082419 — intervention group
Group type: COMPARATOR
Intervention: Control group with no identification of EBSLN during thyroid surgery.
Number of subjects: 42
Study 19293130 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate switch to 4.6 mg/24 h rivastigmine transdermal patch
Number of subjects: 0
Study 19293130 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed switch to 4.6 mg/24 h rivastigmine transdermal patch
Number of subjects: 0
Study 19293130 — intervention group
Group type: COMPARATOR
Intervention: Donepezil 5-10 mg/day
Number of subjects: 0
Study 17501956 — intervention group
Group type: EXPERIMENTAL
Intervention: TCHM (Chinese herbal medicine concoction), 3 capsules twice daily for 12 weeks
Number of subjects: 85
Study 17501956 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 3 capsules twice daily for 12 weeks
Number of subjects: 85
Study 17501956 — intervention group
Group type: EXPERIMENTAL
Intervention: TCHM (Chinese herbal medicine concoction)
Number of subjects: 85
Study 15494274 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hydrocortisone treatment (n = 9)
Number of subjects: 16
Study 15494274 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 16
Study 15494274 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hydrocortisone treatment
Number of subjects: 16
Study 15494274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11847472 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (0.15 IU/kg/day)
Number of subjects: 27
Study 9218038 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization (TUEVAP) with VaporTrode‐Grooved Bar, CIRCON ACMI, power settings 120 to 190 W.
Number of subjects: 12
Study 9218038 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP), power settings 120 to 190 W.
Number of subjects: 12
Study 9218038 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization (TUEVAP) in large prostates.
Number of subjects: 12
Study 9218038 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization (TUEVAP) in small prostates.
Number of subjects: 12
Study 8263071 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-bicisate
Number of subjects: 105
Study 8263071 — intervention group
Group type: COMPARATOR
Intervention: 133Xe
Number of subjects: 105
Study 2889554 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol (2 mg, administered orally)
Number of subjects: 10
Study 2889554 — intervention group
Group type: EXPERIMENTAL
Intervention: Bopindolol (2 to 4 mg, administered orally)
Number of subjects: 10
Study 28857785 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA‐S
Number of subjects: 106
Study 28857785 — intervention group
Group type: COMPARATOR
Intervention: i‐gel
Number of subjects: 106
Study 27160490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal magnesium sulphate (375 μg/rat) prior to intrathecal morphine (10 μg/rat)
Number of subjects: 3
Study 27160490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal mixture of 1 mg of morphine with 3 mL hyperbaric 0.5% bupivacaine
Number of subjects: 3
Study 27160490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal mixture of morphine with bupivacaine and 50 mg of magnesium sulphate
Number of subjects: 3
Study 27160490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal mixture of morphine bupivacaine plus IV 20 mg/kg of magnesium sulphate as a loading dose over 15 min, followed by infusion at a rate of 10 mg/kg/h
Number of subjects: 3
Study 24895810 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) plus standard medical treatment
Number of subjects: 70
Study 24895810 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 70
Study 22266041 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (E1594 and E4599)
Number of subjects: 1590
Study 22266041 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab treatment (E4599)
Number of subjects: 1590
Study 20543666 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated oscillometric BP measuring device (eBPM)
Number of subjects: 3776
Study 20543666 — intervention group
Group type: COMPARATOR
Intervention: Conventional AuscBPM
Number of subjects: 3776
Study 20543666 — intervention group
Group type: EXPERIMENTAL
Intervention: eBPM
Number of subjects: 3776
Study 18408919 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg tandospirone
Number of subjects: 15
Study 18408919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15900355 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 63
Study 15900355 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 63
Study 15900355 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin 25 mg
Number of subjects: 63
Study 15900355 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg (non-chewing controls)
Number of subjects: 63
Study 12611560 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation
Number of subjects: 0
Study 12611560 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of antioxidants
Number of subjects: 0
Study 10875051 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment (mainly antidepressants)
Number of subjects: 210
Study 10875051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behaviour therapy
Number of subjects: 210
Study 10875051 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐help therapy
Number of subjects: 210
Study 10875051 — intervention group
Group type: COMPARATOR
Intervention: Life events (conflict events)
Number of subjects: 210
Study 10875051 — intervention group
Group type: COMPARATOR
Intervention: Life events (loss and addition events)
Number of subjects: 210
Study 10875051 — intervention group
Group type: COMPARATOR
Intervention: Personality characteristics (flamboyant and dependent personality disorders)
Number of subjects: 210
Study 8897030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise at 50% VO2max (two 30-min bouts with 45 min rest)
Number of subjects: 11
Study 8897030 — intervention group
Group type: COMPARATOR
Intervention: Sitting at 23 degrees C for 3 hours
Number of subjects: 11
Study 8897030 — intervention group
Group type: COMPARATOR
Intervention: Sitting at 40 degrees C, 30% relative humidity for 3 hours
Number of subjects: 11
Study 1400010 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ng.kg‐1.min‐1 epinephrine
Number of subjects: 10
Study 1400010 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 ng.kg‐1.min‐1 epinephrine
Number of subjects: 10
Study 1400010 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 ng.kg‐1.min‐1 epinephrine
Number of subjects: 10
Study 1400010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2860180 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% povidone-iodine (PVP-I)
Number of subjects: 56
Study 2860180 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 56
Study 29992608 — intervention group
Group type: EXPERIMENTAL
Intervention: Teen PEP (intervention group)
Number of subjects: 0
Study 29992608 — intervention group
Group type: COMPARATOR
Intervention: Delayed implementation of Teen PEP (comparison group)
Number of subjects: 0
Study 26869460 — intervention group
Group type: EXPERIMENTAL
Intervention: One daily physical exercise unit at school for 4 years
Number of subjects: 366
Study 26869460 — intervention group
Group type: COMPARATOR
Intervention: Conventional school sports twice a week
Number of subjects: 366
Study 26869460 — intervention group
Group type: EXPERIMENTAL
Intervention: One daily physical exercise unit at school
Number of subjects: 366
Study 26573456 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 34
Study 23116325 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-hCG
Number of subjects: 147
Study 23116325 — intervention group
Group type: COMPARATOR
Intervention: r-hCG
Number of subjects: 147
Study 21851602 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract containing 150 mg EGCG two times daily
Number of subjects: 2534
Study 21851602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2534
Study 18676350 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous darbepoetin alfa
Number of subjects: 114
Study 18676350 — intervention group
Group type: COMPARATOR
Intervention: Intravenous darbepoetin alfa
Number of subjects: 114
Study 16367882 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4 mg once daily plus glipizide 10 mg twice daily
Number of subjects: 227
Study 16367882 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea (SU) dose escalation plus placebo
Number of subjects: 227
Study 16367882 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) plus glipizide
Number of subjects: 227
Study 16367882 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylurea (SU) dose escalation
Number of subjects: 227
Study 12635001 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ambient particulates (CAP) at an average concentration of 174 micro g/m(3) for 2 hours with alternating rest-exercise periods.
Number of subjects: 24
Study 12635001 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA) as control.
Number of subjects: 24
Study 12635001 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated ambient particulates (CAP) exposure.
Number of subjects: 24
Study 10982510 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie group (56F bougie)
Number of subjects: 171
Study 10982510 — intervention group
Group type: COMPARATOR
Intervention: No bougie group
Number of subjects: 171
Study 10982510 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie group
Number of subjects: 171
Study 10982510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 171
Study 8630131 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Departments (EDs)
Number of subjects: 123
Study 8630131 — intervention group
Group type: COMPARATOR
Intervention: Private Practitioners
Number of subjects: 123
Study 1360991 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (50 mg)
Number of subjects: 27
Study 1360991 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenindamine (25 mg)
Number of subjects: 27
Study 6581756 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright artificial light therapy
Number of subjects: 29
Study 6581756 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 29
Study 31577721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue strengthening exercise (TSE) with a 1-repetition maximum resistance level of 70%
Number of subjects: 40
Study 31577721 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue strengthening exercise (TSE)
Number of subjects: 40
Study 31577721 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study 29503316 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician
Number of subjects: 1401
Study 29503316 — intervention group
Group type: COMPARATOR
Intervention: Provider type (physician vs. physician extender)
Number of subjects: 1401
Study 26836840 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 40
Study 26836840 — intervention group
Group type: COMPARATOR
Intervention: Control (no vibration stimulus)
Number of subjects: 40
Study 25005674 — intervention group
Group type: EXPERIMENTAL
Intervention: FII algorithm
Number of subjects: 11
Study 25005674 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate counting
Number of subjects: 11
Study 25005674 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 11
Study 23178916 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus adjunctive topical therapy (calcipotriol/betamethasone dipropionate)
Number of subjects: 0
Study 23178916 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab plus matching topical vehicle (monotherapy)
Number of subjects: 0
Study 23178916 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab treatment
Number of subjects: 0
Study 21128217 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) training
Number of subjects: 0
Study 21128217 — intervention group
Group type: COMPARATOR
Intervention: Attention skills training (control condition)
Number of subjects: 0
Study 21128217 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta/beta training
Number of subjects: 0
Study 21128217 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of slow cortical potentials (SCP)
Number of subjects: 0
Study 17487936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid initiation of quetiapine (n = 139)
Number of subjects: 269
Study 17487936 — intervention group
Group type: COMPARATOR
Intervention: Conventional initiation of quetiapine (n = 130)
Number of subjects: 269
Study 17487936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid initiation of quetiapine
Number of subjects: 269
Study 17487936 — intervention group
Group type: COMPARATOR
Intervention: Conventional initiation of quetiapine
Number of subjects: 269
Study 17487936 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Rapid and Conventional)
Number of subjects: 269
Study 15578006 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine (10‐20 mg/day)
Number of subjects: 52
Study 15578006 — intervention group
Group type: COMPARATOR
Intervention: amisulpride (400‐800 mg/day)
Number of subjects: 52
Study 12388024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fornix-based flap
Number of subjects: 30
Study 12388024 — intervention group
Group type: COMPARATOR
Intervention: Limbus-based flap
Number of subjects: 30
Study 10414731 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 555
Study 10414731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 7480923 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin testing with T12E antigen
Number of subjects: 120
Study 7480923 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemagglutination
Number of subjects: 120
Study 7480923 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin testing with T12E antigen and Hemagglutination
Number of subjects: 120
Study 7480923 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin testing, Immunofluorescence, and Hemagglutination
Number of subjects: 120
Study 7480923 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one of the exams (Skin testing, Hemagglutination, Immunofluorescence)
Number of subjects: 120
Study 7480923 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin testing and Immunofluorescence
Number of subjects: 120
Study 10149538 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapur separator with 0.5 mum pore size
Number of subjects: 100
Study 10149538 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapur separator with 0.6 mum pore size
Number of subjects: 100
Study 6340453 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.2 mg/kg over 10 minutes)
Number of subjects: 25
Study 31325962 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy followed by insertion of Surgicel (Group CS)
Number of subjects: 200
Study 31325962 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic drainage followed by insertion of Surgicel (Group DS)
Number of subjects: 200
Study 31325962 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic drainage of the endometrioma (Group D)
Number of subjects: 200
Study 31325962 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cystectomy of the endometrioma (Group C)
Number of subjects: 200
Study 30144303 — intervention group
Group type: EXPERIMENTAL
Intervention: Antrostomy close to the sinus floor (group A)
Number of subjects: 24
Study 30144303 — intervention group
Group type: EXPERIMENTAL
Intervention: Antrostomy cranially positioned (group B)
Number of subjects: 24
Study 27548249 — intervention group
Group type: COMPARATOR
Intervention: Iron therapy (6 mg·kg·day) plus placebo
Number of subjects: 36
Study 27548249 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron therapy (6 mg·kg·day) plus vitamin E (18 mg/day)
Number of subjects: 36
Study 27548249 — intervention group
Group type: COMPARATOR
Intervention: Iron therapy (6 mg·kg·day) plus placebo and vitamin E
Number of subjects: 36
Study 25246781 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth program for 9 months
Number of subjects: 29
Study 25246781 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 29
Study 22353359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal fluid creatinine measurement in confirmed group (Group I)
Number of subjects: 180
Study 22353359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal fluid creatinine measurement in suspected group (Group II)
Number of subjects: 180
Study 22353359 — intervention group
Group type: COMPARATOR
Intervention: Vaginal fluid creatinine measurement in control group (Group III)
Number of subjects: 180
Study 20624806 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-funded RCTs
Number of subjects: 0
Study 20624806 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral/educational trials
Number of subjects: 0
Study 20624806 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered trials
Number of subjects: 0
Study 17379118 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous blood sampling
Number of subjects: 100
Study 17379118 — intervention group
Group type: COMPARATOR
Intervention: Central venous blood sampling
Number of subjects: 100
Study 17379118 — intervention group
Group type: COMPARATOR
Intervention: Radial artery blood sampling
Number of subjects: 100